304 related articles for article (PubMed ID: 21158687)
1. Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.
Huang XP; Mangano T; Hufeisen S; Setola V; Roth BL
Assay Drug Dev Technol; 2010 Dec; 8(6):727-42. PubMed ID: 21158687
[TBL] [Abstract][Full Text] [Related]
2. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.
Schmalhofer WA; Swensen AM; Thomas BS; Felix JP; Haedo RJ; Solly K; Kiss L; Kaczorowski GJ; Garcia ML
Assay Drug Dev Technol; 2010 Dec; 8(6):714-26. PubMed ID: 21158686
[TBL] [Abstract][Full Text] [Related]
3. Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.
Bridal TR; Margulis M; Wang X; Donio M; Sorota S
Assay Drug Dev Technol; 2010 Dec; 8(6):755-65. PubMed ID: 20658944
[TBL] [Abstract][Full Text] [Related]
4. A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.
Titus SA; Beacham D; Shahane SA; Southall N; Xia M; Huang R; Hooten E; Zhao Y; Shou L; Austin CP; Zheng W
Anal Biochem; 2009 Nov; 394(1):30-8. PubMed ID: 19583963
[TBL] [Abstract][Full Text] [Related]
5. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
6. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel.
Murphy SM; Palmer M; Poole MF; Padegimas L; Hunady K; Danzig J; Gill S; Gill R; Ting A; Sherf B; Brunden K; Stricker-Krongrad A
J Pharmacol Toxicol Methods; 2006; 54(1):42-55. PubMed ID: 16326118
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
Potet F; Lorinc AN; Chaigne S; Hopkins CR; Venkataraman R; Stepanovic SZ; Lewis LM; Days E; Sidorov VY; Engers DW; Zou B; Afshartous D; George AL; Campbell CM; Balser JR; Li M; Baudenbacher FJ; Lindsley CW; Weaver CD; Kupershmidt S
J Biol Chem; 2012 Nov; 287(47):39613-25. PubMed ID: 23033485
[TBL] [Abstract][Full Text] [Related]
9. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.
Gillie DJ; Novick SJ; Donovan BT; Payne LA; Townsend C
J Pharmacol Toxicol Methods; 2013; 67(1):33-44. PubMed ID: 23103595
[TBL] [Abstract][Full Text] [Related]
10. Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
Yu Z; Klaasse E; Heitman LH; Ijzerman AP
Toxicol Appl Pharmacol; 2014 Jan; 274(1):78-86. PubMed ID: 24200993
[TBL] [Abstract][Full Text] [Related]
11. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
13. Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.
Xia M; Shahane SA; Huang R; Titus SA; Shum E; Zhao Y; Southall N; Zheng W; Witt KL; Tice RR; Austin CP
Toxicol Appl Pharmacol; 2011 May; 252(3):250-8. PubMed ID: 21362439
[TBL] [Abstract][Full Text] [Related]
14. Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
Guo J; Gang H; Zhang S
J Pharmacol Exp Ther; 2006 May; 317(2):865-74. PubMed ID: 16397089
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis.
DU CY; El Harchi A; Zhang YH; Orchard CH; Hancox JC
J Cardiovasc Electrophysiol; 2011 Oct; 22(10):1163-70. PubMed ID: 21489024
[TBL] [Abstract][Full Text] [Related]
16. Propofol inhibits hERG K
Han SN; Jing Y; Yang LL; Zhang Z; Zhang LR
Eur J Pharmacol; 2016 Nov; 791():168-178. PubMed ID: 27575519
[TBL] [Abstract][Full Text] [Related]
17. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
18. Profiling diverse compounds by flux- and electrophysiology-based primary screens for inhibition of human Ether-à-go-go related gene potassium channels.
Zou B; Yu H; Babcock JJ; Chanda P; Bader JS; McManus OB; Li M
Assay Drug Dev Technol; 2010 Dec; 8(6):743-54. PubMed ID: 21158688
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of hERG potassium channel blockade by antipsychotics.
Silvestre JS; Prous JR
Methods Find Exp Clin Pharmacol; 2007 Sep; 29(7):457-65. PubMed ID: 17982510
[TBL] [Abstract][Full Text] [Related]
20. Microfluidic cell culture and its application in high-throughput drug screening: cardiotoxicity assay for hERG channels.
Su X; Young EW; Underkofler HA; Kamp TJ; January CT; Beebe DJ
J Biomol Screen; 2011 Jan; 16(1):101-11. PubMed ID: 21131594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
